203 related articles for article (PubMed ID: 38057728)
1. Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis.
Naghdi S; Underwood M; Madan J; Brown A; Duncan C; Matharu M; Aksentyte A; Davies N; Rees S; Cooklin A; Grove A; Mistry H
J Headache Pain; 2023 Dec; 24(1):164. PubMed ID: 38057728
[TBL] [Abstract][Full Text] [Related]
2. Competing treatments for migraine: a headache for decision-makers.
Mistry H; Naghdi S; Underwood M; Duncan C; Madan J; Matharu M
J Headache Pain; 2023 Dec; 24(1):162. PubMed ID: 38053051
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
[TBL] [Abstract][Full Text] [Related]
4. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials.
Masoud AT; Hasan MT; Sayed A; Edward HN; Amer AM; Naga AE; Elfil M; Alghamdi BS; Perveen A; Ashraf GM; Bahbah EI
J Neurol Sci; 2021 Aug; 427():117505. PubMed ID: 34082147
[TBL] [Abstract][Full Text] [Related]
7. Topiramate, acupuncture, and BoNT-A for chronic migraine: a network meta-analysis.
Zheng H; Huang SL; Chen YY; Tang TC; Qin D; Chen M
Acta Neurol Scand; 2021 May; 143(5):558-568. PubMed ID: 33393102
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
11. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
Sun W; Cheng H; Xia B; Liu X; Li Y; Wang X; Liu C
Clin J Pain; 2023 Oct; 39(10):560-569. PubMed ID: 37278480
[TBL] [Abstract][Full Text] [Related]
13. Topiramate for the prophylaxis of episodic migraine in adults.
Linde M; Mulleners WM; Chronicle EP; McCrory DC
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD010610. PubMed ID: 23797676
[TBL] [Abstract][Full Text] [Related]
14. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
[TBL] [Abstract][Full Text] [Related]
15. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
Friedman DI; Cohen JM
Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
[TBL] [Abstract][Full Text] [Related]
16. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
17. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
[TBL] [Abstract][Full Text] [Related]
19. Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.
Brandes JL; Kudrow D; Yeung PP; Sakai F; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
Cephalalgia; 2020 Apr; 40(5):470-477. PubMed ID: 31752521
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]